Skip to main content
Clinical Trials/JPRN-jRCTb040190122
JPRN-jRCTb040190122
Recruiting
Phase 2

Efficacy of cultured epidermal autograft in the treatment of vitiligo, refractory scar and refractory skin ulcer. - Efficacy of cultured epidermal autograft for skin disease

Toriyama Kazuhiro0 sites60 target enrollmentMarch 2, 2020

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
vitiligo, refractory scar and refractory skin ulcer
Sponsor
Toriyama Kazuhiro
Enrollment
60
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 2, 2020
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Toriyama Kazuhiro

Eligibility Criteria

Inclusion Criteria

  • (1\) The person who has vitiligo, refractory scar and refractory skin ulcer more than six months
  • (2\) The person who understand and consent this clinical trial. The necessity of written consent by legal representatives (parents, guardians) as well as by the principal when the person is restricted in the age (from 16 to 20\). Additionally, The necessity of written consent by legal representatives (parents, guardians) when the person is under 16 year od age.
  • (3\) Negative in the prescribed infection inspection (hepatitis B, hepatitis C, syphilis, human immunodeficincy virus, adult T cell leukemia)

Exclusion Criteria

  • (1\) Allergy to antibiotic (penicillin, kanamycin, streptomycin, amphotericin B), medical history of allergy to penicillins and aminoglycoside.
  • (2\) Allergy to animals (cow, mouse, pig)
  • (3\) Suspected , present illness and medical history of skin malignant tumor
  • (4\) Difficulty of participation due to mental disorder
  • (5\) Pregnant, lactating woman and possibility of pregnancy
  • (6\) Skin Infectious disease requiring systemic medical treatment
  • (7\) Positive in the prescribed infection inspection (hepatitis B, hepatitis C, syphilis, human immunodeficincy virus, adult T cell leukemia)
  • (8\) Not suitable for this clinical trial from the view oint of the doctors who perform regenerative medicine

Outcomes

Primary Outcomes

Not specified

Similar Trials